Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral formulations of branaplam

A composition and drug technology, applied in the field of treatment, cyclodextrin, prevention or improvement of diseases related to SMN deficiency, can solve the problems of incompatibility of preservatives, poor stability, poor solubility and the like

Pending Publication Date: 2021-08-06
NOVARTIS AG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Indeed, the development of such formulations has been severely hampered by several technical challenges, such as the poor solubility of brenalan in aqueous media (even in the presence of surfactants), pH-dependent stability ( poor stability at pH 4) and the incompatibility of brenella with some preservatives (such as potassium sorbate)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral formulations of branaplam
  • Oral formulations of branaplam
  • Oral formulations of branaplam

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Embodiment 1: a kind of pharmaceutical composition, described pharmaceutical composition comprises

[0115] A) compounds of formula (I)

[0116]

[0117] or a pharmaceutically acceptable salt thereof, and

[0118] B) A pharmaceutically acceptable cyclodextrin or a combination of pharmaceutically acceptable cyclodextrins.

Embodiment 2

[0119] Embodiment 2: The pharmaceutical composition according to embodiment 1, wherein the compound of formula (I) is in the form of its hydrochloride salt.

Embodiment 3

[0120] Embodiment 3: The pharmaceutical composition according to embodiment 1 or 2, wherein the cyclodextrin is β-cyclodextrin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to pharmaceutical compositions suitable for oral administration comprising 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol (branaplam) and a pharmaceutically acceptable cyclodextrin.

Description

technical field [0001] The present invention relates to a pediatric pharmaceutical composition suitable for oral administration comprising 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidine-4 -yl)oxy)pyridazin-3-yl)phenol (INN: branaplam) and pharmaceutically acceptable cyclodextrin. In particular, the present invention relates to such compositions comprising hydroxypropyl-beta-cyclodextrin, one or more flavor enhancers / taste-masking agents and being free of preservatives. The present invention further provides a method of treating, preventing or ameliorating a disorder associated with SMN deficiency, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition disclosed herein. Background technique [0002] Proximal spinal muscular atrophy (SMA) is a group of inherited, clinically heterogeneous neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord. Muscle weakness i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/08A61K31/00A61K47/40
CPCA61K9/0095A61K9/08A61K47/40A61K9/0053A61K31/501A61K47/26A61P25/28A61P21/00A61K47/46
Inventor R·洛瓦莱卡M·德拉斯皮德T·法勒C·豪格P·A·费尔南德斯戈麦斯多斯桑托斯
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com